These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35537414)

  • 1. Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report.
    Kang S; Magliocca J; Sellers M; Roccaro G; Zheng W; Pectasides M; Draper A; Guadagno J; El-Rayes B; Akce M
    Oncol Res Treat; 2022; 45(7-8):430-437. PubMed ID: 35537414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
    Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
    J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Experiences with Triple Immunochemotherapy in Adolescents and Young Adults with High-Risk Fibrolamellar Carcinoma.
    Gottlieb S; O'Grady C; Gliksberg A; Kent P
    Oncology; 2021; 99(5):310-317. PubMed ID: 33690232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the molecular pathogenesis, diagnosis and treatment of fibrolamellar hepatocellular carcinoma: A state of art review of the current literature.
    Alshareefy Y; Shen CY; Prekash RJ
    Pathol Res Pract; 2023 Aug; 248():154655. PubMed ID: 37429175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy.
    Silva NN; Eng C
    J Adv Pract Oncol; 2012 May; 3(3):161-9. PubMed ID: 25031942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrolamellar carcinoma: Challenging the challenge.
    Lamarca A; Frizziero M; Fulton A; McNamara MG; Filobbos R; Hubner RA; Wardell S; Valle JW
    Eur J Cancer; 2020 Sep; 137():144-147. PubMed ID: 32768872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GalNAc-conjugated siRNA targeting the DNAJB1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma.
    Neumayer C; Ng D; Requena D; Jiang CS; Qureshi A; Vaughan R; Prakash TP; Revenko A; Simon SM
    Mol Ther; 2024 Jan; 32(1):140-151. PubMed ID: 37980543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased Protein Kinase A Activity Induces Fibrolamellar Hepatocellular Carcinoma Features Independent of DNAJB1.
    Shirani M; Levin S; Shebl B; Requena D; Finkelstein TM; Johnson DS; Ng D; Lalazar G; Heissel S; Hojrup P; Molina H; de Jong YP; Rice CM; Singhi AD; Torbenson MS; Coffino P; Lyons B; Simon SM
    Cancer Res; 2024 Aug; 84(16):2626-2644. PubMed ID: 38888469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma.
    Bauer J; Köhler N; Maringer Y; Bucher P; Bilich T; Zwick M; Dicks S; Nelde A; Dubbelaar M; Scheid J; Wacker M; Heitmann JS; Schroeder S; Rieth J; Denk M; Richter M; Klein R; Bonzheim I; Luibrand J; Holzer U; Ebinger M; Brecht IB; Bitzer M; Boerries M; Feucht J; Salih HR; Rammensee HG; Hailfinger S; Walz JS
    Nat Commun; 2022 Oct; 13(1):6401. PubMed ID: 36302754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.
    Hackenbruch C; Bauer J; Heitmann JS; Maringer Y; Nelde A; Denk M; Zieschang L; Kammer C; Federmann B; Jung S; Martus P; Malek NP; Nikolaou K; Salih HR; Bitzer M; Walz JS
    Front Oncol; 2024; 14():1367450. PubMed ID: 38606105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver.
    El Dika I; Bowman AS; Berger MF; Capanu M; Chou JF; Benayed R; Zehir A; Shia J; O'Reilly EM; Klimstra DS; Solit DB; Abou-Alfa GK
    Cancer; 2020 Sep; 126(18):4126-4135. PubMed ID: 32663328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Surgical therapy of hepatic fibrolamellar carcinoma].
    Meriggi F; Forni E
    Ann Ital Chir; 2007; 78(1):53-8. PubMed ID: 17518332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA.
    Neumayer C; Ng D; Jiang CS; Qureshi A; Lalazar G; Vaughan R; Simon SM
    Clin Cancer Res; 2023 Jan; 29(1):271-278. PubMed ID: 36302174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.
    Patt YZ; Hassan MM; Lozano RD; Brown TD; Vauthey JN; Curley SA; Ellis LM
    J Clin Oncol; 2003 Feb; 21(3):421-7. PubMed ID: 12560429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Long Non-Coding RNA Profiles and Potential Therapeutic Agents for Fibrolamellar Carcinoma Based on RNA-Sequencing Data.
    Kim J; Kim Y; Lee B
    Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab.
    Berger R; Dinstag G; Tirosh O; Schiff E; Kleiner D; Aldape KD; Ruppin E; Beker T; Kurzrock R
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
    Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
    Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma.
    Kirk AM; Crawford JC; Chou CH; Guy C; Pandey K; Kozlik T; Shah RK; Chung S; Nguyen P; Zhang X; Wang J; Bell M; Mettelman RC; Allen EK; Pogorelyy MV; Kim H; Minervina AA; Awad W; Bajracharya R; White T; Long D; Gordon B; Morrison M; Glazer ES; Murphy AJ; Jiang Y; Fitzpatrick EA; Yarchoan M; Sethupathy P; Croft NP; Purcell AW; Federico SM; Stewart E; Gottschalk S; Zamora AE; DeRenzo C; Strome SE; Thomas PG
    Cell Rep Med; 2024 Mar; 5(3):101469. PubMed ID: 38508137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A genomic case study of mixed fibrolamellar hepatocellular carcinoma.
    Griffith OL; Griffith M; Krysiak K; Magrini V; Ramu A; Skidmore ZL; Kunisaki J; Austin R; McGrath S; Zhang J; Demeter R; Graves T; Eldred JM; Walker J; Larson DE; Maher CA; Lin Y; Chapman W; Mahadevan A; Miksad R; Nasser I; Hanto DW; Mardis ER
    Ann Oncol; 2016 Jun; 27(6):1148-1154. PubMed ID: 27029710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiomic analysis of microRNA-mediated regulation reveals a proliferative axis involving miR-10b in fibrolamellar carcinoma.
    Francisco AB; Kanke M; Massa AP; Dinh TA; Sritharan R; Vakili K; Bardeesy N; Sethupathy P
    JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35482409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.